BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Galvus (Vildagliptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Galvus (Vildagliptin)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06951334-296@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galvus (Vildagliptin): Phase na readout est. (NCT06951334)
DESCRIPTION:Galvus (Vildagliptin)\, phase na.\nStudy: Clinical Trial of Vil
 dagliptin in Early Parkinson's Disease\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vildagl
 iptin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06951334
URL:https://assetmemo.bio/drug/vildagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811011-296@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270320
DTEND;VALUE=DATE:20270321
SUMMARY:Galvus (Vildagliptin): Phase 2/3 readout est. (NCT07811011)
DESCRIPTION:Galvus (Vildagliptin)\, phase 2/3.\nStudy: Efficacy of Vildagli
 ptin Versus Metformin in Patients With Polycystic Ovary Syndrome\nEstimate
 d primary completion: 20 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/vildagliptin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07811011
URL:https://assetmemo.bio/drug/vildagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03925701-296@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Galvus (Vildagliptin): Phase 3 readout est. (NCT03925701)
DESCRIPTION:Galvus (Vildagliptin)\, phase 3.\nStudy: Clinical Study Evaluat
 ing Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/vildagliptin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03925701
URL:https://assetmemo.bio/drug/vildagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
